Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch

Core Insights - Scilex Holding Company announced that Pain Medicine News published retrospective claims data indicating that its product ZTlido® is associated with decreased opioid utilization compared to the 5% lidocaine patch in patients with neuropathic pain [1][2][5] Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, and is forming a joint venture with IPMC Company to address neurodegenerative and cardiometabolic diseases [1][7] - The company’s flagship product, ZTlido® (lidocaine topical system 1.8%), is FDA-approved for neuropathic pain relief associated with postherpetic neuralgia [7] Study Findings - The study revealed that 51.9% of patients treated with ZTlido® experienced a decrease or discontinuation of opioid use compared to 45.5% for those treated with the 5% lidocaine patch [5][6] - Among patients reporting a decrease in opioid use, 21.3% in the ZTlido® group had a reduction of 20% or greater, compared to 13.4% in the 5% lidocaine patch group [5][6] - Patients using ZTlido® showed a non-significant change in baseline opioid use (+3.1%), while those on the 5% patch experienced a significant increase (+42.9%) [5][6] Product Pipeline - Scilex has additional products including ELYXYB®, an FDA-approved oral solution for acute migraine treatment, and Gloperba®, a liquid oral version of colchicine for gout flare prophylaxis [7][8] - The company is also developing three product candidates: SP-102 for lumbosacral radicular pain, SP-103 as a next-generation lidocaine formulation, and SP-104 for fibromyalgia [8]